Skip to navigation Skip to content

Briumvi

Share

About this Medication
  • Brand Name: Briumvi™ (bree-um’-vee)
  • Chemical Name: ublituximab-xiiy
  • Usage in MS: Disease-Modifying Agent
  • Generic Available: No
This medication is taken by intravenous (IV) infusion.
 

Description

Briumvi is a monoclonal antibody that binds to a molecule (CD20) on the surface of immune cells called B cells and depletes (removes) them from circulating in the blood. B cells have several functions including making antibodies, and evidence suggests they play a role in the damage to the brain and spinal cord in MS.

Briumvi is approved by the FDA for the treatment relapsing forms of multiple sclerosis in adults, which include clinically isolated syndrome, relapsing-remitting MS and active secondary progressive MS.

Click to read the Prescribing Information for healthcare professionals.
Click to read the Medication Guide for patients.
 

Support

Briumvi Patient Support
1-833-274-8684
briumvipatientsupport.com
 

Financial Assistance Program

Briumvi Patient Support
1-833-274-8684
briumvipatientsupport.com

Infusion Center Resources

National Infusion Center Association - non-profit patient advocacy organization which offers an online Infusion Center Finder to locate centers throughout the U.S. that administer IV/injectable medications. NICA also provides online consumer education to help patients learn more about infusion services.
 

Share

© 2023 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.